Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab

Fig. 2

Clinical course of the case study and motor and sensory nerve conduction study. A With prednisolone (PSL) treatment, clinical symptoms and peripheral blood eosinophil count decreased. Ten months after administration of prednisolone, signs of relapse were observed and mepolizumab was added. Nerve conduction study (NCS) was performed 3 months after prednisolone (PSL) treatment (NCS①) and 4 months after mepolizumab treatment (NCS②). Motor nerve conduction amplitude in the right tibial nerves (ankle and popliteal) was reduced 3 months after prednisolone treatment (B), and improved 4 months after mepolizumab treatment (D). Similarly, sensory nerve conduction amplitude in the right sural nerves (ankle and popliteal) was decreased 3 months after prednisolone treatment (C) and improved 4 months after mepolizumab treatment (E). PSL: prednisolone, NRS: numeric rating scale, NCS: nerve conduction study, Eo: eosinophil count

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us